home / stock / agio / agio quote
Last: | $34.34 |
---|---|
Change Percent: | 0.0% |
Open: | $35 |
Close: | $34.34 |
High: | $35.015 |
Low: | $34.07 |
Volume: | 654,883 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$34.34 | $35 | $34.34 | $35.015 | $34.07 | 654,883 | 05-17-2024 |
$35 | $35.16 | $35 | $35.2 | $34.82 | 360,179 | 05-16-2024 |
$35.18 | $34.49 | $35.18 | $35.33 | $34.3 | 524,740 | 05-15-2024 |
$34.14 | $33.55 | $34.14 | $34.19 | $33.2 | 506,023 | 05-14-2024 |
$33.54 | $33.4 | $33.54 | $33.66 | $32.77 | 560,367 | 05-13-2024 |
$33 | $32.94 | $33 | $33.09 | $32.45 | 506,066 | 05-10-2024 |
$32.92 | $32.76 | $32.92 | $33.59 | $32.25 | 868,027 | 05-09-2024 |
$32.46 | $32.42 | $32.46 | $32.75 | $31.84 | 773,298 | 05-08-2024 |
$32.8 | $33.47 | $32.8 | $33.515 | $32.52 | 708,140 | 05-07-2024 |
$33.22 | $34.76 | $33.22 | $35.11 | $33.21 | 684,123 | 05-06-2024 |
$34.54 | $34.9 | $34.54 | $35.48 | $33.63 | 807,894 | 05-03-2024 |
$34.58 | $33.59 | $34.58 | $35.36 | $33.16 | 694,335 | 05-02-2024 |
$33.66 | $32.3 | $33.66 | $34.58 | $32.3 | 857,317 | 05-01-2024 |
$32.5 | $32.63 | $32.5 | $33.3 | $31.77 | 660,890 | 04-30-2024 |
$32.76 | $31.5 | $32.76 | $33.215 | $31.5 | 734,933 | 04-29-2024 |
$31.49 | $31.7 | $31.49 | $32.01 | $31.31 | 419,310 | 04-26-2024 |
$31.67 | $31.22 | $31.67 | $32.25 | $31.215 | 721,957 | 04-25-2024 |
$31.67 | $32.08 | $31.67 | $32.26 | $31.32 | 544,491 | 04-24-2024 |
$31.81 | $30.4 | $31.81 | $33.02 | $30.4 | 1,224,626 | 04-23-2024 |
$30.21 | $29.66 | $30.21 | $30.89 | $29.5 | 861,755 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Agios Pharmaceuticals Inc. Company Name:
AGIO Stock Symbol:
NASDAQ Market:
Agios Pharmaceuticals Inc. Website:
At the RBC Global Healthcare Conference, held on 14-15 May, RBC’s Healthcare Desk Sector Strategist gauged biotech investor sentime...
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional P...
– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session – – Additional Presentations to Highlight Quality of Life Data from ENERGIZE and Design of the Phase 3 RISE UP Study of Mitapivat in Sic...